Gavi, the Vaccine Alliance, will purchase 500,000 doses of MVA-BN, the Bavarian Nordic Mpox vaccine, to combat the Mpox outbreak in Africa. The purchase is made possible by Gavi’s First Response Fund, aimed at quick vaccine procurement during health crises. The World Health Organisation recently approved the MVA-BN vaccine, streamlining the procurement process for global organizations. The doses will be distributed to affected countries this year. Gavi CEO Dr Sania Nishtar expressed gratitude to donors for funding the First Response Fund. African CDC has requested 10 million doses, with only 3.6 million secured so far. Kenya received ACAM2000 vaccine for preparedness, allocating funds for response. Surveillance and response measures have been strengthened in the country to contain the outbreak.
[ad_2]
Source link
